AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
Improved overall survival, progression-free survival seen, including among patients with low PD-L1 expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.